23June

Oral semaglutide demonstrated significant reduction in blood sugar vs placebo in ... Read more

23June

Ozempic® provided greater weight reductions for adults with a baseline BMI of or ... Read more

23June

Tresiba® demonstrated significantly improved blood sugar control and lower rates ... Read more

23June

Significant blood sugar improvement with Xultophy® compared to insulin glargine ... Read more

20June

Oral semaglutide shows statistically significantly greater reductions in HbA1c a ... Read more

19June

Novo Nordisk A/S - Share repurchase programme ... Read more

11June

Novo Nordisk A/S - Share repurchase programme ... Read more

04June

Novo Nordisk A/S - Share repurchase programme ... Read more

24June

Novo Nordisk's investor and analyst event at ADA 2018, Orlando

01July

Silent period,

08August

Financial statement for the first six months of 2018,

28August

Commerzbank Sector Conference, Frankfurt

 

 

 

Investors

 
Share information


Take an advanced view of the Novo Nordisk share

 
Annual Report 2017 


Click here to find further information

 
Q1 2018 financial results


Novo Nordisk at a glance


Private shareholders


See relevant content for private investors



IR material


Download relevant Investor Relations material



Contacts



Subscriptions


Sign up to receive company announcements.


ADA investor and analyst event